Affibody AB

📢 Join Us at #PEPTalk 2025! Affibody's CSO, Fredrik Frejd, PhD, will be presenting on January 15th at 8:20am during the “Targeted Radioligand Therapies” session. Presentation Title: Expanding Targeted Radioligand Therapy to HER2-Expressing Breast Cancer Using Affibody Molecules as Targeting Vectors 🗓 Date: January 15, 2025 🕗 Time: 8:20 am 📌 Session: Targeted Radioligand Therapies Breast cancer remains a leading cause of cancer-related mortality among women. HER2 is a critical oncogenic driver in many breast cancers, making it a key target for molecular radiotherapy. Clinical imaging using HER2 specific Affibody® PET tracer has demonstrated binding to the target in women with metastatic disease. Based on the same technology, Affibody® molecule ABY-271 has been optimised to achieve a favourable tissue distribution profile and is in advanced preclinical development for targeted radioligand therapy. ⭐ Don’t miss this opportunity to learn how Affibody® molecules are driving innovations in molecular radiotherapy and advancing cancer treatment. We look forward to seeing you there!

🎉 Happy New Year! 🎉 As 2024 draws to a close, we’re feeling inspired by the progress we’ve made in the last year. Some of our highlights include: Best-in-class results from late-stage trials of izokibep in both Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA). Submission of clinical trial application for the first-in-man study of our lead radiotherapeutic candidate, ABY-271, in patients with HER2 expressing metastatic breast cancer. Expanded use of our HER2 PET radiodiagnostic, tezatabep (ABY-025), in clinical studies in Thailand and Poland, as well as in clinical studies in Sweden on solid tumors outside of breast cancer, i.e. gastroesophageal cancer. Now, we’re looking forward to the year ahead and we have some exciting things lined up – stay tuned! Wishing everyone a happy, healthy, and successful 2025! 🥂

🎄✨ Happy Holidays from the Affibody team! ✨🎄   It’s been another year of great achievements and we’ve hit some exciting milestones.    We’d like to thank our team and supporters for your continued support in helping us drive the development of our next generation biopharmaceuticals.    We wish you all a joyful festive season!

At Affibody, our mission is to transform the future of healthcare through the development of innovative biotherapeutics! With our Affibody® technology platform, we are designing novel molecules that target diseases with precision, offering new hope to patients with unmet medical needs. Our current focus areas include oncology, autoimmune diseases, and inflammatory conditions. We are developing therapies that specifically target HER2-positive cancers, immune-driven diseases such as asthma, and other complex disorders that conventional treatments struggle to address. The properties of Affibody® molecules allows for more efficacious blocking by using multi-specific constructs, as shown in clinical trials in autoimmune diseases. Together with our partners, we hope to bring life-changing therapies to those who need them most. Find out more about what we do! https://www.affibody.se/ #Biotechnology #Oncology #AutoimmuneDiseases

Today is an important day for protein science, as we celebrate David Baker, Demis Hassabis, and John Jumper, recipients of the 2024 Nobel Prize in Chemistry. At Affibody, we share their passion for protein science and its promise for improving the lives of patients. Their innovative use of AI in unravelling protein complexities has transformed our field and underpins our daily work in the development of next-generation biopharmaceuticals. Here's to future discoveries and advancements in the world of proteins! 🚀

Our Director of Translational Medicine, Nina Eissler, just delivered her talk at the Targeted Radiopharmaceuticals Summit Europe, which we are delighted was well received.   Nina shared insights into Affibody’s work in developing a theranostic pair for molecular imaging and precision medicine, targeting HER2, a key oncogenic driver overexpressed in various solid tumours.    She highlighted how the Affibody PET tracer, tezatabep matraxetan (ABY-025), can identify HER2-positive tumor lesions in their anatomical context, enabling patient stratification for HER2-targeted therapies and providing a window into disease heterogeneity. She also discussed how through advanced protein engineering, the radiotherapeutic candidate ABY-271 has been optimised to achieve a favourable tissue distribution profile. Preclinical studies show that ABY-271 has promising efficacy and a balanced safety profile. Early results from the first-in-human study in breast cancer are expected in 2025. 

We're excited to share that our Director of Translational Medicine, Nina Eissler, will be presenting at the Targeted Radiopharmaceuticals Summit Europe in Amsterdam on December 5th!   At 12:00 pm, Nina will discuss the exciting potential of Affibody molecules as theranostics in molecular imaging and treatment of HER2-expressing cancers. Her presentation, titled "Exploring Affibody Molecules as Vehicles for Molecular Radiotherapy of HER2-Expressing Malignancies," will highlight:   ✅ Why image-guided decisions are proving superior to traditional immunohistochemistry for patient selection. ✅ How the PET tracer ABY-025 demonstrates improved patient selection and treatment response prediction. ✅ The development of ABY-271 as a promising candidate for radioligand therapy targeting HER2-expressing malignancies with early results from the first-in-human study in breast cancer expected in 2025.   For those attending the summit, don't miss this session!   Get in touch if you would like to schedule a meeting with Nina: reception@affibody.com

Our innovative Affibody® molecules can be attached to radioactive agents for precise tumor targeting. Once injected, these molecules quickly find and bind to specific surface proteins on cancer cells, where they remain to deliver highly focused radiation. This precision minimizes damage to healthy tissue and helps initiate the body's immune system to detect and kill any remaining cancer cells. This unique mechanism offers potential for combination therapies with immuno-oncology drugs. In collaboration with esteemed academic institutions and GE HealthCare, we are driving progress in oncology with leading candidates ABY-025 and GE-226, PET tracers that enable non-invasive imaging of HER2 expression in cancers like breast and gastric cancer. These tracers help detect HER2 levels and monitor therapy response, expanding treatment options for more patients. Learn more about our pipeline: https://lnkd.in/dukR7hcG #Oncology #Antibodies

Great news for Affibody as well!

It was fantastic to see such an engaged audience at our CSO Fredrik Frejd’s presentation yesterday at #PEGSEurope, who showed interest in learning about the engineering of optimised Affibody-based radiopharmaceuticals.    This event truly brought together experts who appreciate and are committed to addressing the challenge of achieving balanced distribution for optimal efficacy and tolerability.   A big thank you to everyone who attended and for your enthusiasm in our work!